# Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

> **NCT05493709** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 93 (estimated)

## Conditions studied

- Puberty; Precocious, Central

## Interventions

- **DRUG:** Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide

## Key facts

- **NCT ID:** NCT05493709
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-02
- **Primary completion:** 2025-11
- **Final completion:** 2026-06
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05493709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05493709, "Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05493709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*